Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 6/20 | 0.33 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592596 | 0.84 | MAP4K1 (0.36) | ALDH1A1MEN1KMT2AKDM4EGAA | |
| SCHEMBL4777017 | 0.84 | NPC1 (0.34) | ALDH1A1MEN1KMT2AKDM4EGAA | |
| SCHEMBL4662894 | 0.82 | ACSS2 (0.34) | ALDH1A1ERN1BRD4ACSS2HSP90AA1 | |
| SCHEMBL4664646 | 0.82 | PDE9A (0.40) | ALDH1A1KDM4EGAAPABPC1HPGD | |
| SCHEMBL25301126 | 0.81 | ACLY (0.33) | ALDH1A1SMN1; SMN2ERN1 | |
| SCHEMBL30482620 | 0.81 | ACLY (0.33) | ALDH1A1SMN1; SMN2ERN1 | |
| SCHEMBL4663143 | 0.81 | HDAC4 (0.35) | ALDH1A1GAANPC1RAB9AERN1 | |
| SCHEMBL4664802 | 0.80 | BRD4 (0.36) | ALDH1A1HSD17B10POLBSMN1; SMN2BRD4 | |
| SCHEMBL4633246 | 0.80 | LMNA (0.42) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL3558933 | 0.79 | KDM4E (0.49) | ALDH1A1MEN1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718809-B2 | Chromane substituted benzimidazole derivatives as acid pump antagonists | RAQUALIA PHARMA INC. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1893197-B1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | RAQUALIA PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | HRH2, HRH4, HRH1 | ALDH1A1 2368/4885MEN1 3429/4885KMT2A 4564/4885 |
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | ALDH1A1 293/4885MEN1 3164/4885KMT2A 3220/4885 |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | ALDH1A1 576/4885MEN1 2551/4885KMT2A 4095/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | ALDH1A1 2588/4885MEN1 2783/4885KMT2A 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.